Close Menu

NEW YORK (GenomeWeb) – Taiwanese diagnostics firm PlexBio said today that it received CE marking for its IntelliPlex Lung Cancer Panel, an in vitro molecular diagnostic assay for the qualitative identification of 36 DNA mutations.

The assay can identify mutations in the KRAS, NRAS, PIK3CA, BRAF, and EGFR genes, as well as 19 gene rearrangements of the ALK, ROS1, RET, NTRK1, and MET genes from formalin-fixed, paraffin-embedded tumor tissue from lung cancer patients, PlexBio said. It added that the assay leverages its SelectAmp and πCode technologies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Guardian reports that the Mammalian Genetics Unit at the Harwell Institute is to close.

Scientific research itself contributes to plastic waste and isn't very sustainable, FiveThirtyEight reports.

Restaurants in the US may soon serve AquaBounty's genetically modified salmon, according to the Associated Press.

In Science this week: three studies from the Ruminant Genome Project, and more.

Jul
23
Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
24
Sponsored by
Hologic

This webinar will share the results of comparisons of commercially available nucleic acid amplification tests for use in routine screening of pregnant women for Group B Streptococcus (GBS).

Jul
25
Sponsored by
Roche

This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.